These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 4889058)

  • 21. Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients.
    Ramsay RA; Ban TA; Lehmann HE; Saxena BM; Bennett J
    Can Med Assoc J; 1970 May; 102(9):939-42. PubMed ID: 4157149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A standard-controlled clinical study with propericiazine in schizophrenic patients.
    Ananth JV; Ban TA
    Psychopharmacol Bull; 1977 Jul; 13(3):19-20. PubMed ID: 18754
    [No Abstract]   [Full Text] [Related]  

  • 23. The use of LSD and ditran in the treatment of therapy resistant schizophrenics (symptom provocation approach).
    Itil TM; Keskiner S; Holden JM
    Dis Nerv Syst; 1969 Feb; 30(2):Suppl:93-103. PubMed ID: 4388281
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Arango C; Bernardo M
    Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Violence and schizophrenia: clozapine as a specific antiaggressive agent.
    Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC
    Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study.
    Sterlin C; Augustin E; Ban TA; Jarrold L
    Curr Ther Res Clin Exp; 1971 Jan; 13(1):50-2. PubMed ID: 4992566
    [No Abstract]   [Full Text] [Related]  

  • 27. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients.
    Lehmann HE; Ban TA; Lee H
    Curr Ther Res Clin Exp; 1967 Jan; 9(1):36-7. PubMed ID: 4963021
    [No Abstract]   [Full Text] [Related]  

  • 29. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients.
    Amin MM; Brahm E; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):10-1. PubMed ID: 18753
    [No Abstract]   [Full Text] [Related]  

  • 30. Piperacetazine (Quide): a controlled evaluation of the elixir in chronic schizophrenic patients.
    Gallant DM; Bishop MP
    Curr Ther Res Clin Exp; 1970 Jun; 12(6):387-9. PubMed ID: 4987346
    [No Abstract]   [Full Text] [Related]  

  • 31. Schizophrenia as a disorder of neuro-psychological control mechanisms.
    Dussik KT
    Dis Nerv Syst; 1968 May; 29(5):Suppl:68-77. PubMed ID: 5673626
    [No Abstract]   [Full Text] [Related]  

  • 32. A clinical trial of a benzazepine (SCH 12679) in acute schizophrenic patients.
    Park S; Gershon S; Floyd A
    Curr Ther Res Clin Exp; 1972 Jun; 14(6):298-302. PubMed ID: 4625801
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical trial of flupenthixol decanoate in chronic withdrawn schizophrenic patients.
    Vichaiya V
    J Med Assoc Thai; 1980 Apr; 63(4):205-9. PubMed ID: 6991627
    [No Abstract]   [Full Text] [Related]  

  • 34. Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study.
    Ananth JV; Vacaflor L; Kekhwa G; Sterlin C; Ban TA
    Int Z Klin Pharmakol Ther Toxikol; 1972 Feb; 5(4):406-10. PubMed ID: 4261601
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of chronic schizophrenic psychoses with a thioridazine derivative].
    Glatzel J
    Med Welt; 1972 Jan; 23(2):62-4. PubMed ID: 5059991
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of dopamine agonists in the treatment of schizophrenia.
    Corsini GU; Pitzalis GF; Bernardi F; Bocchetta A; Del Zompo M
    Neuropharmacology; 1981 Dec; 20(12B):1309-13. PubMed ID: 7033816
    [No Abstract]   [Full Text] [Related]  

  • 37. Controlled study of BL-KR140 on chronic anergic schizophrenic patients stabilized with a neuroleptic compound.
    Dim BH; Kurland AA
    Curr Ther Res Clin Exp; 1968 Jun; 10(6):288-91. PubMed ID: 4969835
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparative trial of oxypertine and chlorpromazine in the treatment of acute psychoses.
    Wadzisz FJ
    Curr Ther Res Clin Exp; 1969 Dec; 11(12):784-92. PubMed ID: 4984044
    [No Abstract]   [Full Text] [Related]  

  • 39. Two pilot studies of AHR-1680 in chronic schizophrenic patients.
    Sugerman AA; Herrmann J; O'Hara M; Simpson GM; Angus JW; Deutsch L
    J Clin Pharmacol J New Drugs; 1969; 9(3):183-6. PubMed ID: 4892454
    [No Abstract]   [Full Text] [Related]  

  • 40. SCH-12041 in the treatment of acute schizophrenic patients.
    Ota KY; Kurland AA; Ferro-Diaz P
    Curr Ther Res Clin Exp; 1973 Jun; 15(6):327-32. PubMed ID: 4197257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.